Pharmaceuticals

HUA MEDICINE-B

Hualead Pharmaceutical Reports Significant 2025 Performance, Huatangning Commercialization Fully On Track

Huapro Pharma Announces 2025 Annual Results: Huatangning Sales Increase by 91%

HUA MEDICINE-B released FY2025 9 Months Earnings on March 26 (BJT), actual revenue HKD 386.01 M, actual EPS HKD 1.2456

HUA MEDICINE-B released FY2025 Q3 earnings on March 26, 2026 (BJT) with actual revenue of HKD 150.58 M and EPS of HKD -0.0427

HUA MEDICINE-B released FY2025 earnings on March 26 Pre-Market (BJT), actual revenue HKD 538.76 M (forecast HKD 541 M), actual EPS HKD 1.2022 (forecast HKD 0.884)

HUA MEDICINE-B released FY2025 Q4 earnings on March 26 Pre-Market (BJT), actual revenue HKD 153.18 M, actual EPS HKD -0.0435

HUA MEDICINE-B to release FY2025 earnings on March 26 Pre-Market (BJT), forecast revenue HKD 532 M, EPS HKD 0.8693

Huagui Medicine Obtains Approval for Drug Dorzagliatin for Type 2 Diabetes

Huaer Medicine Initiates HMS1005 Clinical Trial for Type 2 Diabetes in the US

Huameng Medicine Experiences Rapid Sales Growth Post Commercialization Takeover and Pushes Development of Second-Generation GKA

Huamedx-B Sees Significant Revenue Growth in H1 2025, Aims for Over 1 Billion Yuan in 2027

HUA MEDICINE-B released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 116.43 M, actual EPS HKD 0.6372

Hu Lun Pharmaceutical Reports Turnaround in Mid-Year Earnings After Bayer Agreement Termination

HUA MEDICINE-B released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue HKD 118.99 M, actual EPS HKD 0.6512

HUA MEDICINE-B released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue HKD 235.42 M, actual EPS HKD 1.2884

HUA MEDICINE-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Chen Li Indicates China's Innovative Drugs Account for 38% of the Global Market and Introduces Huatangning Product

Group Terminates Bayer Agreement, Fully Takes Over Xtlair® Commercial Operations

Huailung Medicine Predicts Significant Profit Growth in 2025

Dr. Fangxin Li Resigns from Hualein Pharmaceutical's Board and Remuneration Committee

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02552

02659

03069

Yesterday, HUA MEDICINE-B triggered a golden cross signal on the daily MACD zero axis in the Hong Kong stock market, with a trading volume of approximately HKD 4.68 million, which is considered a normal high level for this unprofitable biotech stock. The confirmation of the golden cross above the zero axis on the MACD indicates that a medium-term bullish pattern is beginning to take shape, and buying pressure is accumulating in stages. HUA MEDICINE focuses on the research and development of innovative drugs for diabetes, and its stock price has gradually rebounded from a state of extreme sluggishness, with initial signs of a bottom forming. On the news front, the overall biotech sector in the Hong Kong stock market has recently stabilized after a decline. The news that BAO PHARMA has been included in the MSCI Global Small Cap Index has attracted market attention, indicating a renewed recognition of the value of innovative pharmaceutical companies by international capital. The trading activity of the group of Hong Kong 18A biotech companies has recently increased, with some stocks experiencing unusual capital movements. In addition, frequent mergers and acquisitions in the global pharmaceutical industry have heightened market attention to the pipeline value of unprofitable biotech companies, which could serve as a potential catalyst for R&D-focused pharmaceutical companies like HUA MEDICINE. From a technical perspective, HUA MEDICINE-B has limited liquidity, with a low average daily trading volume, so the reference value of technical signals needs to be assessed in conjunction with changes in trading volume. If the trading volume can maintain above HKD 4 million in subsequent trading days and is accompanied by a positive closing price, the reliability of the signal will be enhanced. The overall trend of the biotech sector and the capital flow of similar 18A stocks are important references. The short-term trend is biased towards bullish but should be approached with caution, as technical signals for small-cap, low-liquidity stocks can easily be distorted by large single orders. Attention should be paid to the company's pipeline progress and changes in sector sentiment

Technical Forecast

BAO PHARMA-B

CAM HSBIOTECH

Pre-market trend | HUA MEDICINE-B (2552.HK) Bullish signals emerging on 5/14, is there an undercurrent in innovative small-cap stocks?

Hua Medicine (HK:2552) is seeking shareholder approval to update its constitutional documents, allowing for electronic or hybrid general meetings and electronic voting. This change aims to enhance corporate governance flexibility. The proposed amendments will be presented for approval at the upcoming annual general meeting, with details to be shared in a circular to shareholders. The company, based in the Cayman Islands, emphasizes strong corporate governance with a diverse board structure. Current market cap stands at HK$3.74B with a strong buy sentiment in trading.

Tip Ranks

Hua Medicine Seeks Shareholder Approval for Digital-Friendly Articles Update

Hua Medicine announced its 2025 annual results, reporting a 91% increase in sales of HuaTangNing, reaching RMB 492.9 million in revenue. The company achieved a profit before tax of RMB 1,106.4 million and improved gross margins to 56.9%. HuaTangNing was renewed in the National Reimbursement Drug List, and market exclusivity in China was extended to 2034. The company also expanded its global presence with the approval of dorzagliatin in Hong Kong. CEO Dr. Li Chen highlighted the transition to a fully independent commercialization operation, achieving significant growth and profitability in the diabetes treatment sector.

Asian Corporate Newswire

Hua Medicine Announces 2025 Annual Results

159849

159506

159837

513700

520880

159316

520690

512290

159892

510660

HUA MEDICINE-B announced its 2025 annual results, with revenue of 493 million RMB, an increase of 92.6% year-on-year. It recorded a net profit of 1.106 billion RMB, compared to a loss of 250 million RMB in the previous year, turning from loss to profit; earnings per share were 1.12 RMB. No final dividend is declared

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

"Performance" HUA MEDICINE's annual net profit is 1.106 billion RMB, turning losses into profits

Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

Hua Medicine has received marketing approval for its glucokinase activator, dorzagliatin (MYHOMSIS(R)), in Hong Kong, marking the first GKA approval outside mainland China. This innovative treatment for Type 2 diabetes will serve as a launchpad for the company's international expansion. The approval follows the acceptance of its New Drug Application under Hong Kong's "1+" regulatory mechanism. The drug aims to improve glucose sensitivity and restore glycemic homeostasis, differentiating it from existing therapies. Hua Medicine plans to leverage this approval to build a marketing network and advance clinical expansion in the Greater Bay Area.

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

A glucokinase-activator (GKA) has received its first approval outside mainland China, marking a significant milestone in the management of Type 2 diabetes (T2D). This approval signifies a unique approach to T2D treatment. Hong Kong has been chosen by Hua Medicine as the springboard for their expansion into the international market. The decision was made public in Shanghai and Hong Kong on March 3, 2026.

Unusual Whales

HK approves dorzagliatin by Hua Medicine for T2D management, first GKA approval outside China. Launchpad for international expansion.

HUA MEDICINE-B(02552.HK)

Pre-market trend | HUA MEDICINE-B (2552.HK) Bullish signals emerging on 5/14, is there an undercurrent in innovative small-cap stocks?

Hua Medicine Seeks Shareholder Approval for Digital-Friendly Articles Update

Hua Medicine Announces 2025 Annual Results

"Performance" HUA MEDICINE's annual net profit is 1.106 billion RMB, turning losses into profits

Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

HK approves dorzagliatin by Hua Medicine for T2D management, first GKA approval outside China. Launchpad for international expansion.